ARDAMAN SHERGILL
Prescription History 1992948152
Internal Medicine - Medical Oncology in Chicago, IL


Quality Rating: 97.71 out of 100 score

NPI Status: Active since April 16, 2009

Contact Information

5841 S MARYLAND AVE
CHICAGO, IL
ZIP 60637
Phone: (888) 824-0200

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ARDAMAN SHERGILL, an active Medical Oncology specialist practicing in Chicago, IL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 52 documented patient claims. Among these therapy options, the most frequently utilized medication is Creon, which accounts for 15 claims alone.

Medication Index

No matching medications currently found on file.

Creon

Generic Formulation: Lipase/Protease/AmylaseSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 452
IL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills32.7
Peer Average Days Supply871
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,130.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,408.70

State Avg Cost Per Claim

$1,434.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. It is used in conditions where the pancreas cannot make or does not release enough digestive enzymes into the small intestines to digest the food (conditions such as chronic pancreatitis, cystic fibrosis, cancer of the pancreas, post-pancreatectomy, post-gastrointestinal bypass surgery).

Lisinopril

Generic Formulation: LisinoprilSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.2
Days Supply 455
IL State Average Benchmarks
Peer Average Claims117.0
Peer Average 30-Day Fills286.2
Peer Average Days Supply8,464
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 88.9% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $82.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.36

State Avg Cost Per Claim

$8.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Therapeutic Applications

Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 18.0
Days Supply 540
IL State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills68.8
Peer Average Days Supply1,880
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.6% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $169.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.41

State Avg Cost Per Claim

$23.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 331
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills33.8
Peer Average Days Supply409
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.6% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $232.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.86

State Avg Cost Per Claim

$6.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ARDAMAN SHERGILL provides transparency into local medical care patterns within Chicago, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.